205 related articles for article (PubMed ID: 22057638)
1. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM; Mostafa MF; El-Gendi AM
Pathol Oncol Res; 2012 Apr; 18(2):459-69. PubMed ID: 22057638
[TBL] [Abstract][Full Text] [Related]
2. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK; Dasgupta A; Sotgia F; Mercier I; Pestell RG; Sabel M; Kleer CG; Brody JR; Lisanti MP
Am J Pathol; 2009 Jun; 174(6):2023-34. PubMed ID: 19411448
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis.
Jia Y; Wang N; Wang J; Tian H; Ma W; Wang K; Tan B; Zhang G; Yang S; Bai B; Cheng Y
Ann Surg Oncol; 2014 Jan; 21(1):329-36. PubMed ID: 23982252
[TBL] [Abstract][Full Text] [Related]
4. Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer.
Eliyatkin N; Aktas S; Diniz G; Ozgur HH; Ekin ZY; Kupelioglu A
Pathol Oncol Res; 2018 Jan; 24(1):59-65. PubMed ID: 28236153
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of caveolin in breast cancer: a meta-analysis.
Ma X; Liu L; Nie W; Li Y; Zhang B; Zhang J; Zhou R
Breast; 2013 Aug; 22(4):462-9. PubMed ID: 23639584
[TBL] [Abstract][Full Text] [Related]
6. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.
Witkiewicz AK; Dasgupta A; Nguyen KH; Liu C; Kovatich AJ; Schwartz GF; Pestell RG; Sotgia F; Rui H; Lisanti MP
Cancer Biol Ther; 2009 Jun; 8(11):1071-9. PubMed ID: 19502809
[TBL] [Abstract][Full Text] [Related]
7. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract][Full Text] [Related]
8. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
11. Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival.
Zhao Z; Han FH; Yang SB; Hua LX; Wu JH; Zhan WH
World J Gastroenterol; 2015 Jan; 21(4):1140-7. PubMed ID: 25632186
[TBL] [Abstract][Full Text] [Related]
12. Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.
Saeed-Vafa D; Marchion DC; McCarthy SM; Hakam A; Lopez A; Wenham RM; Apte SM; Chen DT; Magliocco AM; Lancaster JM; Reid BM; Permuth JB
PLoS One; 2021; 16(11):e0256615. PubMed ID: 34813586
[TBL] [Abstract][Full Text] [Related]
13. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.
Witkiewicz AK; Whitaker-Menezes D; Dasgupta A; Philp NJ; Lin Z; Gandara R; Sneddon S; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2012 Mar; 11(6):1108-17. PubMed ID: 22313602
[TBL] [Abstract][Full Text] [Related]
14. Stromal cell expression of caveolin-1 predicts outcome in breast cancer.
Sloan EK; Ciocca DR; Pouliot N; Natoli A; Restall C; Henderson MA; Fanelli MA; Cuello-Carrión FD; Gago FE; Anderson RL
Am J Pathol; 2009 Jun; 174(6):2035-43. PubMed ID: 19411449
[TBL] [Abstract][Full Text] [Related]
15. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
16. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.
Ranogajec I; Jakić-Razumović J; Puzović V; Gabrilovac J
Med Oncol; 2012 Jun; 29(2):561-9. PubMed ID: 21611838
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment.
Sotgia F; Martinez-Outschoorn UE; Pavlides S; Howell A; Pestell RG; Lisanti MP
Breast Cancer Res; 2011 Jul; 13(4):213. PubMed ID: 21867571
[TBL] [Abstract][Full Text] [Related]
19. Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome.
Ren M; Liu F; Zhu Y; Li Y; Lang R; Fan Y; Gu F; Zhang X; Fu L
Virchows Arch; 2014 Sep; 465(3):291-8. PubMed ID: 24980157
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
